Glenmark launches nasal spray in India for treating allergic rhinitis

Glenmark launches nasal spray in India for treating allergic rhinitis
Glenmark launches nasal spray in India for treating allergic rhinitis
03 May 2021 | News
Glenmark becomes the first company in the world to launch Ryaltris®-AZ as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
image credit- shutterstock
Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, announced the launch of Ryaltris®-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India.

Related Keywords

Mumbai ,Maharashtra ,India ,Alok Malik ,Group Vice ,Glenmark Pharmaceuticals ,Glenmark Pharmaceuticals Limited ,Group Vice President ,Business Head ,India Formulations ,Glenmark ,Nasal ,Company ,Launch ,மும்பை ,மகாராஷ்டிரா ,இந்தியா ,அலோக் மாலிக் ,குழு துணை ,க்ளேண்மர்க் மருந்துகள் ,க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை ,குழு துணை ப்ரெஸிடெஂட் ,வணிக தலை ,இந்தியா சூத்திரங்கள் ,க்ளேண்மர்க் ,